Screener
Theravance Biopharma TBPH Pre-Tax Income
Pre-Tax Income at other companies
Other financials
Where this comes from
Reported directly by Theravance Biopharma in its filing.
Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.
The source filing: Theravance Biopharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 9:00 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-056760
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Loss from operations | (9,483) | (14,434) |
| Interest expense (non-cash) | — | (643) |
| Interest and other income, net | 3,013 | 939 |
| Loss before income taxes | (6,470) | (14,138) |
| Provision for income tax benefit | 1,537 | 559 |
| Net loss | (4,933) | (13,579) |
| Net unrealized loss on available-for-sale investments | (123) | (7) |
| Total comprehensive loss | $(5,056) | $(13,586) |
Item 1. Financial Statements (unaudited)
FAQ
- What is Theravance Biopharma's pre-tax income?
- Theravance Biopharma (TBPH) reported pre-tax income of -$6.47M in Q1 2026.
- How has Theravance Biopharma's pre-tax income changed year-over-year?
- Theravance Biopharma's pre-tax income increased by 54.2% year-over-year, from -$14.14M to -$6.47M.
- What is the long-term trend for Theravance Biopharma's pre-tax income?
- Over 4 years (2021 to 2025), Theravance Biopharma's pre-tax income has grown at a -14.9% compound annual growth rate (CAGR), from -$245.96M to $129.25M.
- What does pre-tax income mean?
- Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.
Ask your AI about Theravance Biopharma's pre-tax income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude